Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients

Sponsor
Diamant Thaci
Study ID
NCT03146247
Phase
PHASE4
Status
Withdrawn

Conditions

  • Moderate to Severe Plaque Psoriasis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study aims to identify and describe the presence of itch active molecules in psoriasis and response to treatment with apremilast. This data will be complemented by immunohistochemical data determining nerve ending density and neuropeptide concentrations before and during treatment and correlated with patient reported outcome. It is important to underscore that itch may interfere with various aspects of patient functioning, emotions and social status and should therefore be adequately addressed while treating patients with psoriasis

Key Dates

First listed
May 9, 2017
Start date
Oct 23, 2017
Status verified
Apr 2019
Primary completion
Mar 1, 2019
Completion
Mar 1, 2019

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Other: One arm
    all patients receive same dose and dosing regimen with Apremilast

Primary Outcome Measure

Immunoreactive nerve fibers [ Time Frame: until week 16 ]

Related Studies